Allergy & Clinical Immunology News

• ART Use Rises Among US Medicare Enrollees Living With HIV A recent study showed that rates of antiretroviral therapy in enrollees living with HIV increased over the years, but women had low prescription rates across all age groups.
  Medscape Medical News, December 23, 2024
• MMRV Safety Assessed in Children on Methotrexate, Dupilumab No adverse events were observed in a small retrospective study of pediatric patients receiving the MMRV vaccine while on dupilumab or methotrexate.
  Medscape Medical News, December 20, 2024
• ACR 2024 Post-Exertional Malaise in Fatiguing Diseases: What to Know A new finding of post-exertional malaise in 20% of people with fibromyalgia might be an overestimate, but when post-exertional malaise is present, extreme caution is needed around prescribing exercise.
  Medscape Medical News, December 20, 2024
• ACR 2024 Genetic Markers May Predict TNF Inhibitor Response in RA Genetic markers may help predict response to TNF inhibitor therapy in rheumatoid arthritis, potentially leading to more personalized and effective treatment strategies.
  Medscape Medical News, December 20, 2024
• Prison Needle Exchange Programs Reduce Healthcare Costs Canada’s prison needle exchange programs not only reduce bloodborne infections and injection-related infections but also save healthcare costs.
  Medscape Medical News, December 19, 2024
• CDC Continues Surveillance, USDA Collaboration on H5N1 Medscape Medical News spoke with the CDC expert on the current H5N1 situation in the United States and ongoing surveillance of the disease.
  Medscape Medical News, December 19, 2024
• Skin Cancer Risk Increased After Blood or Marrow Transplant A study reported a cumulative incidence of over 25% for skin cancer after bone or marrow transplant.
  Medscape Medical News, December 19, 2024
• Merck's HIV Treatment Meets Main Goal in Two Late-stage Studies Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in adults receiving another form of therapy in two...
  Reuters Health Information, December 19, 2024
• RSV Vaccine Research in Infants May Proceed With Caution FDA Committee discussed safety concerns but agreed that more data are needed.
  Medscape Medical News, December 19, 2024
• Alert FDA Approves Seventh Ustekinumab Biosimilar, Steqeyma Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.
  Medscape Medical News, December 19, 2024
• MSWS 2024 Traditional Hand Eczema Treatments May Face Obsolescence Nonspecific anti-inflammatories like steroids might be entirely sidelined for mild-to-moderate chronic hand eczema now that three targeted topical agents are available.
  Medscape Medical News, December 18, 2024
• Inhaled Insulin Benefits Kids With Diabetes, Too New data for MannKind’s Afrezza will be used in a supplemental new drug application for a pediatric indication.
  Medscape Medical News, December 18, 2024
• Teva, Sanofi Say Bowel Disease Drug Met Primary Targets (Dec 17) (This Dec.17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5)
  Reuters Health Information, December 17, 2024
• What’s Behind Wild State-by-State Variations in Long COVID? New data show significant state and regional variations in long COVID rates, and experts think they know why.
  Medscape Medical News, December 17, 2024
• How Should Canada Confront the Rise in HIV Infections? The population most affected by HIV has changed in recent years, and public health messaging may not be reaching the appropriate audience.
  Medscape Medical News, December 17, 2024
• CDC Suspends Chagas Disease Testing Some laboratory operations were paused to re-evaluate resources, spokesperson says.
  Medscape Medical News, December 17, 2024
• Severe Shigella Infections Increasing in Homeless Patients The strain causing most of the infections among people experiencing homelessness in Vancouver, Canada, is multidrug-resistant, new research shows.
  Medscape Medical News, December 17, 2024
• Merck Discontinues Development Of 2 Experimental Cancer Drugs After Trial Failures Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
  Reuters Health Information, December 16, 2024
• Alert FDA Approves Topical Tapinarof for Atopic Dermatitis In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was approximately 80 consecutive days.
  Medscape Medical News, December 16, 2024
• MSWS 2024 Integrative Dermatology Addresses Unmet Need When managing complex chronic dermatologic diseases, efforts to incorporate alternative treatments can add efficacy, patient reassurance, and patient engagement.
  Medscape Medical News, December 15, 2024